BeiGene, a clinical-stage biopharmaceutical company focused on immuno-oncology cancer therapeutics, has appointed Amy Peterson, MD, as chief medical officer, immuno-oncology. Dr. Peterson will lead the global clinical development of BGB-A317, BeiGene’s PD-1 inhibitor; BGB-290, BeiGene’s PARP inhibitor; and the expanding pipeline of other immuno-oncology agents expected to enter clinical development.
Dr. Eric Hedrick, currently serving as the interim chief medical officer, will continue to oversee global clinical hematology development including the program for BGB-3111, BeiGene’s BTK inhibitor, and will remain serving as an advisor.
Prior to joining BeiGene, Dr. Peterson was vice president of clinical development at Medivation, where she was primarily responsible for the development of enzalutamide and talazoparib in breast cancer and of pidilizumab in diffuse large b-cell lymphoma. Previously, she served as associate group medical director at Genentech, where she was responsible for the development of early-stage molecules targeting multiple pathways in oncology. Prior to joining Genentech, Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas Gajewski.